Barclays
PRCT icon

Barclays’s Procept Biorobotics PRCT Stock Holding History

Barclays’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,000
Closed -$2.48M – 5434
2024
Q3 		$2.48M Buy
+31,000
New +$2.2M ﹤0.01% 2677

Other funds holding PRCT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Barclays's PRCT Position: Q3 2026 in Review

Barclays increased its Procept Biorobotics (PRCT) stake by 63% in Q3 2026, buying an estimated $2.06M and bringing the position to 266,458 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Barclays first reported a position in PRCT in Q1 2022 and has held it in 19 quarters since. The position peaked at $12.6M in Q4 2024. 171 funds tracked by Wall St. Rank hold PRCT as of Q3 2026.

  • Barclays held 266,458 shares of Procept Biorobotics worth $4.85M as of Q3 2026.
  • Barclays bought 103,102 Procept Biorobotics shares in Q3 2026, an estimated $2.06M.
  • Procept Biorobotics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2063 holding.
  • Barclays first reported a position in Procept Biorobotics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Procept Biorobotics position peaked at $12.6M in Q4 2024.
  • 171 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.